Ultra-Sensitive AML MRD Monitoring

Redefining the “Ultimate Solution” for AML: Ultra-Sensitive MRD Monitoring in a Single Day

By LexigenBio Scientific Team

Acute Myeloid Leukemia (AML) remains one of the most challenging hematologic malignancies, accounting for over 25% of all leukemia cases. In the modern clinical landscape, the focus has shifted from mere diagnosis to the precision of Minimal Residual Disease (MRD) monitoring.

MRD detection is the “early warning system” of oncology—essential for evaluating treatment response, monitoring relapse, and guiding early clinical intervention. However, for years, laboratories have been forced to choose between the speed of flow cytometry (MFC) and the depth of Next-Generation Sequencing (NGS).

Today, LexigenBio is removing that compromise with the LeXso AML MRD Comprehensive Solution.

The NGS Challenge: Silencing the Noise

While NGS is often called the “ultimate solution” for its ability to observe clonal evolution across multiple mutation sites, it has traditionally been hindered by high sequencing costs and background noise. In the hunt for low-frequency clones, distinguishing a true biological mutation from a sequencing error is paramount.

The LeXso solution tackles this through two technical breakthroughs:

1. LeXPrep NEM Fragmentation: Unlike traditional sonication or enzymatic methods that involve polymerase reactions (which can introduce background noise), our Nucleic Acid Endonuclease (NEM) module preserves original sequence information and base modifications.
2. Molecular Identifiers: By tagging each original DNA molecule, our system allows for the detection of ultra-low-frequency mutations (down to 0.025%–0.1% AF) with absolute confidence.

Comprehensive Coverage: No Clone Left Behind

LeXso AML Panel v1.0 isn’t just fast; it’s exhaustive. We curated the panel by referencing COSMIC and TCGA databases to ensure that our 32-gene, 42.5 Kb target region provides 90% coverage of adult AML cases.

Whether you are tracking SNVs, Indels (including challenging FLT3-ITD structural variants), or Gene Fusions, the LeXso panel enriches all critical markers in a single, high-uniformity assay.

Velocity Meets Precision: The Same-Day Workflow

In clinical research, a week-long wait for results is a lifetime. The patented LeXso Hybrid Capture System utilizes optimized kinetics to complete hybridization in just 120 minutes.

Combined with our streamlined library prep, the entire workflow—from raw gDNA to a sequencing-ready library—can be completed within the same day.

Economic Efficiency: Save 80% of Sequencing Volume

High sensitivity usually comes with a high price tag, but LeXso is engineered for efficiency. With an on-target rate exceeding 70%, our solution significantly improves data utilization. For most labs, this translates to saving up to 80% of sequencing volume compared to traditional hybridization methods, allowing for more samples per run and lower costs per patient.

Conclusion: Empowering the Future of Leukemia Research

The LeXso AML MRD Comprehensive Solution represents the convergence of high-fidelity chemistry and rapid clinical utility. By silencing background noise and accelerating the hybrid capture clock, LexigenBio is helping laboratories turn the “ultimate solution” of NGS into a practical, daily reality for AML research.

Ready to accelerate your MRD research? [Request a Technical Solution Consultation] | [LeXso AML MRD Comprehensive Solution] | [Contact support@lexigenbio.com]

Ordering Information:

• LX02801: LeXPrep NEM Fragment Module
• LX11412: LeXso AML Panel v1.0 (16 rxn)
• LX15102: LeXso Hybrid Capture Reagents (High-Speed)

For more information, visit www.lexigenbio.com